https://pittplusme.org/study/1277
HCC-17-203
STUDY BASICS
Have you been diagnosed with hormone receptor positive or triple negative breast cancer that is growing on your chest wall (chest wall disease)? If so, you may be eligible to participate in a study to help researchers see what effects, good or bad, the combination of pembrolizumab (KEYTRUDA) and carboplatin (chemotherapy) have on your cancer compared to carboplatin alone.
IRB: STUDY19110231
- A Randomized Phase II Study of Pembrolizumab, an anti-PD (programmed cell death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease
MEET THE RESEARCHER
Leisha Emens
Leisha Emens, MD, PhD, is Professor of Medicine at the University of Pittsburgh, Co-Leader of the Hillman Cancer Immunology and Immunotherapy Program, and Director of Translational Immunotherapy for the Women's Cancer Research Center at Magee Women's Hospital. Dr. Emens received her MD-PhD from Baylor College of Medicine and completed her residency training in Internal Medicine at the University of Texas at Southwestern before moving to Johns Hopkins for a fellowship in Medical Oncology and Hematology. Dr. Emens specializes in cancer immunotherapy, and her research focuses on the development and implementation of breast cancer immunotherapies in combination with traditional anticancer therapies and newer targeted therapies.